Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

15.32 -0.12 (-0.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 846,150
Open 15.60
Bid (Size) 15.00 (3)
Ask (Size) 16.16 (9)
Prev. Close 15.44
Today's Range 15.06 - 15.60
52wk Range 15.06 - 59.99
Shares Outstanding 59,762,106
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
Via Benzinga

Performance

YTD
-31.85%
-31.85%
1 Month
-20.91%
-20.91%
3 Month
-41.97%
-41.97%
6 Month
-21.60%
-21.60%
1 Year
-66.53%
-66.53%

More News

Read More
Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights
Via Benzinga
Sage Therapeutics to Present at Upcoming March Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results
Via Benzinga
Earnings Scheduled For February 14, 2024
Via Benzinga
The Latest Analyst Ratings for Sage Therapeutics
Via Benzinga
Analyst Ratings for Sage Therapeutics
Via Benzinga
Why Sage Therapeutics Stock Sank Today
Via The Motley Fool
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Changes to Board of Directors
From Sage Therapeutics, Inc.
Via Business Wire
The Latest Analyst Ratings for Sage Therapeutics
Via Benzinga
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
From Sage Therapeutics, Inc.
Via Business Wire
5 Biotech stocks tapping into unmet mental health treatment needs
Via MarketBeat
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Sage Therapeutics, Inc.
Via Business Wire
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Biogen Inc.
Via GlobeNewswire
Sage Therapeutics to Present at Upcoming November Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Earnings Scheduled For November 7, 2023
Via Benzinga
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.